Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935284 | 0.72 | — | — | |
| SCHEMBL22393720 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL206344 | 0.68 | TRPA1 (0.34) | TRPA1 | |
| Quinazoline SCHEMBL5078612 | 0.65 | TRPA1 (0.35) | TRPA1 | |
| SCHEMBL18935567 | 0.65 | — | — | |
| SCHEMBL15075855 | 0.63 | — | — | |
| SCHEMBL29633894 | 0.63 | — | — | |
| SCHEMBL30691872 | 0.63 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL5050147 | 0.63 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL9926021 | 0.63 | TRPA1 (0.58) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | claimed |
| WO-2024127333-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | claimed |
| CN-117263873-A | 1, 4-benzodiazepine compounds and application thereof in preparation of antitumor drugs | 复旦大学 | 2023-12-22 | — | — | CN | claimed |
| WO-2023241738-A2 | 1,4-BENZODIAZEPINE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUG | 复旦大学 | 2023-12-21 | — | — | WO | claimed |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | claimed |
| CN-115925642-A | Synthesis method of 1, 4-benzodiazepine heterocyclic derivative | 枣庄学院 | 2023-04-07 | — | — | CN | claimed |
| CN-115368371-A | Chiral triazine heterocyclic spiro-conjugated 1, 4-benzodiazepine-2-one compound and preparation method thereof | 北京工业大学 | 2022-11-22 | — | — | CN | claimed |
| CN-112851691-B | Chiral oxadiazine heterocyclic compound and preparation method thereof | 北京工业大学 | 2022-10-11 | — | — | CN | claimed |
| CN-112574220-B | Chiral heterocyclic compound and preparation method thereof | 北京工业大学 | 2022-10-11 | — | — | CN | claimed |
| EP-0024272-B1 | 1,4-BENZODIAZEPINES AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Kali-Chemie Pharma GmbH (DE) | 1982-12-08 | — | — | EP | claimed |
| US-4362732-A | Diazepine derivatives and their use | HOFFMANN-LA ROCHE INC. (US) | 1982-12-07 | — | — | US | claimed |
| US-4352817-A | ANTIDOTE FOR TRANQUILLIZING EFFECTS OF 1,4-BENZODIAZEPINES | HOFFMANN-LA ROCHE INC. (US) | 1982-10-05 | — | — | US | claimed |
| US-4352818-A | ANTIDOTES FOR INTOXICATION CAUSED BY 1,4-BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-10-05 | — | — | US | claimed |
| US-4338314-A | [1,2]Anellated-7-phenyl-1,4-benzodiazepine and pharmaceutical compositions thereof and use for treatment of ulcers | KALI-CHEMIE PHARMA GMBH (DE) | 1982-07-06 | — | — | US | claimed |
| US-4316897-A | TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |
| US-4170649-A | 2-SUBSTITUTED BY CYANOMETHYLENE OR CARBAMOYLMETHYLENE, TRANQUILIZERS, OXIDIZING CORRESPONDING CYANOMETHYL COMPOUNDS, OPTIONAL HYDROLYSIS | KALI-CHEMIE PHARMA GMBH (DE) | 1979-10-09 | — | — | US | claimed |
| US-4155904-A | Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones | SCHERING CORPORATION (US) | 1979-05-22 | — | — | US | claimed |
| US-4145417-A | TRANQUILIZERS, SEDATIVES, HYPNOTICS, ADDUCTS WITH ALDEHYDES | DDSA PHARMACEUTICLAS LTD. (GB) | 1979-03-20 | — | — | US | claimed |
| US-4083948-A | IODINE LABELS | HOFFMANN-LA ROCHE, INC. (US) | 1978-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | SRI, PROC, PRDX6 | TRPA1 2870/4885 |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | PNN, HTR1B, GABBR1 | TRPA1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.